Comparative Pharmacology
Head-to-head clinical analysis: AZILECT versus ZELAPAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZILECT versus ZELAPAR.
AZILECT vs ZELAPAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversible selective inhibitor of monoamine oxidase type B (MAO-B), which inhibits the metabolism of dopamine in the brain, increasing dopaminergic activity.
Selective and irreversible inhibitor of monoamine oxidase B (MAO-B), which increases dopamine levels in the striatum by blocking its metabolism.
1 mg orally once daily
1.25 mg sublingually once daily in the morning; may increase to 2.5 mg once daily if needed.
None Documented
None Documented
Terminal elimination half-life of rasagiline is approximately 3-4 hours; however, due to irreversible MAO-B inhibition, the pharmacological effect lasts longer than the elimination half-life.
Terminal elimination half-life: 2-4 hours (selegiline); due to irreversible MAO-B inhibition, clinical effect persists for 24-72 hours after single dose.
Renal (approximately 60% of dose as metabolites, <1% unchanged); fecal (about 20%); small amount exhaled as CO2. Metabolites primarily excreted via urine.
Renal: 70-80% as metabolites (10% as unchanged drug in bile/feces); biliary/fecal: 20-30%.
Category C
Category C
MAO-B Inhibitor
MAO-B Inhibitor